Philosys Co., Ltd. announced that it has received KRW 4 billion in funding from Dongwha Pharm.Co.,Ltd
April 25, 2018
Share
On April 26, 2018, Philosys Co., Ltd. closed the transaction. The company received KRW 2,000,000,000 in its second and final tranche close. The company as received a total of KRW 4,000,000,000 in the transaction.
DONGWHA PHARM.CO., LTD is a Korea-based company engaged in the manufacture of pharmaceuticals. The Companyâs products consist of ethical drugs, including digestive system remedies, antibiotics, cardiovascular and metabolic disease treatments, non steroidal anti-inflammatory drugs, respiratory remedies, muscle relaxants, nervous system remedies, dermatological remedies and urinary system remedies, and over-the-counter (OTC) drugs, including cold remedies, dental remedies, dermatological remedies, hepatic protectors, nutrients, tonics, topical analgesics, anti-smoking agents and others. It also provides medicine raw materials, health food and drinks, as well as cosmetics. The Company distributes its products within domestic market and to overseas markets.
DONGWHA PHARM.CO.,LTD 
